Status:
COMPLETED
The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
AstraZeneca
Teva Branded
Conditions:
Asthma
Eligibility:
All Genders
78-12 years
Phase:
NA
Brief Summary
Background Chronic inflammation in peripheral airways plays an important role in the pathophysiology of asthma. Extrafine hydrofluoroalkane (HFA) beclometasone is distinguished from other ICS because ...
Eligibility Criteria
Inclusion
- age 6.5 - 12 years
- children with mild-persistent asthma
- treatment with inhaled corticosteroids(≤ 500 μg HFA-Flucticasone, ≤ 800 μg Budesonide, or ≤ 800 μg HFA-Beclometasone, daily)
- allowed, but needed to be used during the entire study period;
- short / long-acting β2-agonists
- leukotrien receptor antagonists
- antihistamines
Exclusion
- Instability of asthma during the past 3 months
- Presence of a disease that may intervene with the results of this study
- Active smoking
- Mental retardation
- Inability to perform the measurements properly
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00402207
Start Date
August 1 2005
End Date
October 1 2006
Last Update
November 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Maastricht
Maastricht, Netherlands, 6202 AZ